Emerillon, Sanderling seed PreciThera, plan for Series A round
Canadian venture capital firm Emerillon Capital and U.S. firm Sanderling Ventures have provided seed-stage financing to PreciThera Inc, a Montréal precision medicine company. No financial terms were released. Recently founded by Dr. Philippe Crine and Dr. Susan Schiavi, PreciThera is focused on designing and developing biological agents for the treatment of orphan diseases. The drug development team at Sanderling's Therillia Development Company Inc will support the company as it advances its program. Emerillon and Sanderling said the seed round will help launch PreciThera and prepare it for a Series A backed by Canadian and foreign investors.
10 May 2017•3 mins read
